Canine Atopic Dermatitis Market To Reach $8.78 Billion By 2030

Canine Atopic Dermatitis Market Growth & Trends

The global canine atopic dermatitis market size is anticipated to reach USD 8.78 billion by 2030 and expand at a CAGR of 10.6% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of canine atopic dermatitis and advancements in veterinary medicine are driving market growth. Increasing cases of skin allergies in dogs have led to higher demand for effective treatments. Innovations such as monoclonal antibodies and improved immunosuppressants enhance therapeutic outcomes, fueling market expansion. Research and development efforts continue to drive novel therapies, improving treatment efficacy and accessibility.

Growing pet ownership and increased awareness among pet owners propel the canine atopic dermatitis market. As more households adopt dogs, the demand for dermatological care rises. Pet owners are becoming more proactive in seeking treatment, leading to higher adoption of specialized therapies. The rise in pet healthcare spending and improved diagnostic capabilities further contribute to market growth.

The increasing focus on companion animal wellness and expanding veterinary healthcare infrastructure are expected to drive market growth. Enhanced veterinary facilities and specialized dermatology clinics improve access to advanced treatments. Rising investments in pet healthcare further support the market expansion, with pharmaceutical companies developing innovative solutions to meet growing demand.

 Request a free sample copy or view report summary: Canine Atopic Dermatitis Market Report

Canine Atopic Dermatitis Market Report Highlights

• By product, the glucocorticoids segment led the market with the largest revenue share of 38.3% in 2024, fueled by its widespread use in managing inflammation and allergic reactions in dogs.

• The MAbs segment is set to be the fastest-growing segment during the forecast period,attributed to its targeted approach to managing allergic reactions.

• By type, the prescription segment dominated the market with the largest share in 2024, driven by the growing reliance on veterinarian-recommended treatments.

• The OTC segment is set to witness the fastest growth from 2025 to 2030 due to increasing preference for accessible and affordable treatments.

• North America accounted for the largest revenue share of 40.4% in 2024, propelled by its advanced veterinary healthcare infrastructure and high pet ownership rates.

Canine Atopic Dermatitis Market Segmentation

Grand View Research has segmented the global canine atopic dermatitis market based on product, type, dog breed, mode of administration, indication, distribution channel, and region:

Canine Atopic Dermatitis Product Outlook (Revenue, USD Million, 2018 - 2030)

• Glucocorticoids

• Antihistamines

• Immunosuppressants

• MAbs

• Others

Canine Atopic Dermatitis Type Outlook (Revenue, USD Million, 2018 - 2030)

• Prescription

• OTC

Canine Atopic Dermatitis Dog Breed Outlook (Revenue, USD Million, 2018 - 2030)

• German Shepherd

• Terriers

• Retrievers

• Others

Canine Atopic Dermatitis Mode of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Topical

• Injectable

Canine Atopic Dermatitis Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Ectoparasites

• Food Allergy

• Allergic Skin Infections

• Others

Canine Atopic Dermatitis Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Veterinary Hospitals/Clinics

• Retail

• E-commerce

Canine Atopic Dermatitis Region Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Canine Atopic Dermatitis Market

• Zoetis Services LLC

• Merck & Co., Inc.

• Elanco

• Boehringer Ingelheim International GmbH

• Virbac

• Vetoquinol

• Dechra

• Biofelix Pharma Group

• TORAY INDUSTRIES, INC.

• Bioiberica S.A.U.

• Ceva

• Bimeda, Inc.